CD8A and glioblastoma: In agreement with these findings, RCAN1-422-32-primed CD8+ T cells killed significantly fewer tumor cells when cultured with SF10281 (RCAN1-4neg GBM cells than RCAN1-4pos GBM cells) (Fig. 3I, Supplementary Fig. 7C, D).